About 25% of all immune checkpoint inhibitor recipients in the United States develop moderate-to-severe immune-related enterocolitis, and the standard clinical response to that complication is to pull them off the cancer therapy that may be saving their life. That trade-off is the problem Seres Therapeutics is trying to solve with SER-155, and on July 8 the company will present top-line data from a 15-patient investigator-sponsored trial that could reframe whether the gut microbiome is a serious therapeutic lever in oncology toxicity management.
The trial, conducted at Memorial Sloan Kettering Cancer Center under NCT06801067, enrolled patients with Grade 2–3 immune checkpoint inhibitor-related enterocolitis who had not yet received immunosuppressive therapy. The primary endpoint is immunosuppressive-free clinical response at Day 15, defined as at least a one-grade improvement in diarrhea without touching corticosteroids. That is an exacting binary at a short time horizon: 15 patients, 15 days, one clean threshold. Small trials in open-label designs can mislead, but the specificity of the endpoint and the immunosuppressive-naïve population make the readout interpretable in a way that softer efficacy measures would not be.
The regulatory context adds weight here. SER-155 received Breakthrough Therapy designation in December 2024 for a separate indication: reducing bloodstream infections in allogeneic hematopoietic stem cell transplant recipients. The irEC program sits alongside that primary path as an investigator-sponsored expansion, not a funded company-sponsored pivot, but positive data would meaningfully broaden the asset’s clinical story at a moment when Seres is navigating a leaner balance sheet. Published meta-analyses put the incidence of Grade 3–4 colitis at roughly 1.7% across ICI-treated patients overall, rising sharply with ipilimumab combinations, which signals a commercially relevant population if a steroid-sparing approach can demonstrate durability beyond the Day 15 mark.
The number to watch after July 8 is not the response rate in isolation but whether Seres discloses any signal on ICI therapy continuation. If patients who achieved clinical response were able to restart or maintain checkpoint inhibitor treatment, that outcome redefines SER-155’s value proposition from a supportive-care add-on to an enabler of oncology regimens, a distinction that would carry real weight with oncologists, payers, and any potential partner evaluating the asset.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
